Considering the evolving treatment landscape for ALK+ non-small cell lung cancer (NSCLC), more data are needed for brigatinib in both the post-crizotinib and post-next generation settings, which could help clinicians make informed decisions and maximize patient benefits. The gene discussed is ALK; the disease is non-small cell lung carcinoma.